

# Functional Impact of Sequence Alterations Found in *BRCA1* Promoter/5'UTR Region in Breast/Ovarian Cancer Families from Upper Silesia, Poland

Jolanta Pamuła<sup>1</sup>, Małgorzata Krześniak<sup>2</sup>, Helena Zientek<sup>1</sup>, Wioletta Pękała<sup>1</sup>, Marek Rusin<sup>2</sup>, Ewa Grzybowska<sup>1</sup>

<sup>1</sup>Department of Molecular Biology, <sup>2</sup>Department of Tumour Biology, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice Branch, Poland

**Key words:** *BRCA1* promoter, polymorphism, reporter assay, breast cancer

**Corresponding author:** Jolanta Pamuła, Department of Molecular Biology, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice Branch, ul. Wybrzeże Armii Krajowej 15, 44-102 Gliwice, Poland; fax +48 32 2313512; e-mail: jpamuła@io.gliwice.pl

Submitted: 4 December 2005

Accepted: 10 January 2006

## Abstract

The 5' region of *BRCA1* contains multiple regulatory sequences flanking the two alternative promoters  $\alpha$  and  $\beta$  and two alternative, non-coding exons, 1a and 1b. Aberrations within the 5' region *BRCA1* (encompassing two alternative promoters  $\alpha$  and  $\beta$  and exons 1a and 1b) may be associated with an increased risk of breast and ovarian cancer. In this study we screened 150 patients for polymorphism and mutations in this region of *BRCA1*. All probands came from familial breast and/or ovarian cancer that had been found to be mutation-negative in a previous search for founder mutations in *BRCA1* (185delAG, C61G, 4153delA, 5382insC) or *BRCA2* (6174delT, 9631delC). In our study we found several sequence alterations within the non-coding region of *BRCA1* by using direct DNA sequencing and allele-specific PCR amplification. Three families with a polymorphic deletion in *BRCA1* exon 1b (2223delAAAAA, Acc. U37574) were found. Moreover, two linked nucleotide substitutions (2642A>T, 2743T>C, Acc. U37574) in *BRCA1* intron 1 were detected in 16 patients. In order to assess the functional significance of these two sequence variants, we constructed a reporter vector encoding firefly luciferase under the transcriptional and translational control of wild type and altered *BRCA1* promoter region. The reporter assay was performed using a lung cancer cell line (NCI-H1299) and a breast cancer cell line (MCF7). We have demonstrated that the analysed sequence variants have no functional significance in our experimental system. However, we have found that the *BRCA1* promoter has lower relative activity in the breast cancer cell line compared with the lung cancer cell line. Based on the results of our functional experiments we conclude that the polymorphic deletion 2223delAAAAA and two linked substitutions 2642A>T and 2743T>C do not significantly alter *BRCA1* expression and are probably not disease-causing mutations.

## Introduction

The human *BRCA1* gene is under the transcriptional control of two different promoters,  $\alpha$  and  $\beta$  that drive the transcription of exon 1a and 1b, respectively [22].

At the RNA level each of the alternative first exons is linked by splicing with exon 2 [21]. However, the translational initiation site is the same for the two mRNA variants and is located in exon 2 [11]. The *BRCA1* 5'UTR region coded by exon 1b contains three

additional ATG codons upstream of the major translation initiation site [21]. The promoter  $\alpha$  is bi-directional and shared with the NBR2 gene [4, 21]. *BRCA1* contains multiple transcription factor binding sites identified in 5' flanking regions of exon 1a and exon 1b [17, 18]. The different transcripts of the *BRCA1* gene are present at different levels in various normal and tumour tissues and may have distinct biological functions [21]. Expression of transcripts  $\alpha$  and  $\beta$  of the *BRCA1* gene may be co-regulated by use of a dual promoter system. Moreover, the two mRNAs may differ in their stability or translational efficiency [21].

Germline mutations within the *BRCA1* gene are responsible for familial cancer and reduced expression of the *BRCA1* gene is frequently observed in sporadic breast [12, 16, 20] and ovarian tumours [23]. Various mechanisms such as methylation of the CpG islands within the promoter region [2, 6, 10, 13], allelic deletion of the *BRCA1* locus and sequence alterations identified outside the *BRCA1* coding region, especially within the positive regulatory region (PRR) of the *BRCA1* promoter, can modulate the level of *BRCA1* expression [17, 19]. There are also other mechanisms responsible for breast and ovarian cancer pathogenesis [5, 15]. Expression patterns of *BRCA1* mRNAs and differences in their translatability [14] and disruption of the DNA-protein complexes [18] may also contribute to breast/ovarian cancer susceptibility.

Our aim was to investigate the functional effect of sequence alterations within the *BRCA1* promoter/5'UTR region using luciferase reporter gene assay.

## Material and methods

### Patients

One hundred and fifty patients from families resident in Upper Silesia, Poland, were screened for deletions in the *BRCA1* promoter/5'UTR region using genomic DNA extracted from peripheral blood lymphocytes using the phenol-chloroform method [7]. Each patient was selected after clinical genetic counselling in which they completed a detailed questionnaire, including family history, after signing an informed consent document. Each person selected for the study was diagnosed with breast and/or ovarian cancer and had a positive family history of breast and/or ovarian cancer.

### Screening for new sequence variants within *BRCA1* promoter/5'UTR

Eighty-seven patients diagnosed with breast and/or ovarian cancer were selected for *BRCA1*

promoter/5'UTR (GenBank accession no. U37574) screening by direct DNA sequencing. All patients were mutation-negative for founder mutations in the *BRCA1* gene (185delAG, 300T/G, 4153delA, 5382insC) and in the *BRCA2* gene (6174delT, 9631delC) using ASA-PCR and RFLP PCRs analyses [8, 9].

PCR amplification was performed using the following primers (forward/reverse, 5'→3'): fragment 1 G A C G C T T G G C T C T T T C T G T /TCTGGATCCTCCTCAAGCAC, fragment 2 G A G T G G A T T T C C G A A G C T G A /TCTGGACCTCCTCAAGCAC, fragment 3 G A T G G G A C C T T G T G G A A G A A /CGCGAAGAGCAGATAAAATCC. All reactions were performed in 15  $\mu$ l containing 1  $\mu$ l 50-150 ng DNA, 1xPCR buffer II (50 mM KCl, 10 mM Tris-HCl pH 8.3), 1.5 mM MgCl<sub>2</sub>, 50 pmol each primer and 1U of AmpliTaq DNA Polymerase (Applied Biosystem). The PCR cycling conditions were: fragment 1, 94°C for 30s, 64°C for 30s, 72°C for 30s; fragment 2, 94°C for 30s, 59°C for 30s, 72°C for 30s; fragment 3, 94°C for 30s, 58°C for 30s, 72°C for 30s. An initial denaturation for 5 min. at 95°C and a final extension at 72°C for 7 min. were also included in each PCR reaction. All reactions were carried out for 35 cycles on a GeneAmp™ PCR System 2400 (Applied Biosystem) thermal cycler. PCR products were separated in a 2% agarose gel, 1xTBE, stained with ethidium bromide and analysed using Scion Image Beta 4.02 Win Software (Scion Corporation, USA). Amplified products were purified before sequencing with exonuclease I and shrimp alkaline phosphatase according to the manufacturer's protocol (Amersham Life Science). Both strands were sequenced using the following primers 5'→3': fragment 1 (forward) GACGCTTGGCTCTTCTGTC, fragment 2 (forward) GTAAGGCGTTGTGAACCCTG and fragment 3 (forward) GGAGACAGGATTTTGTGGGA, fragment 1 (reverse) CAGCCTCCTGAGTAGCTGGA fragment 2 (reverse) TCTGGATCCTCCTCAAGCAC fragment 3 (reverse) CGCGAAGAGCAGATAAAATCC. Samples were sequenced with BigDye Terminator Cycle Sequencing Kit v3.1 (Applied Biosystem) and analysed with the ABI Prism 377 DNA automated sequencer (Applied Biosystem).


Allele-specific PCR amplification was used to estimate the frequency of the polymorphic deletion 2223delAAAAA in an additional sixty-three patients of breast/ovarian cancer patients fulfilling the above criteria. The following primers were used: (5'→3')TTTAAAAACGTCGGCTGGTC (forward), TCCACAAAATCCTGTCTCC (reverse) and CAGCCGGTGTGTTTTGTTTT (reverse) with 'touch-

down' PCR: denaturation at 95°C for 5 min. followed by 10 cycles of 94°C 20s, 65°C 25s (at this point temperature decreased 0.7°C per cycle), 72°C 30s and followed by 30 cycles at 94°C 20s, 58°C 25s, 72°C 30s ending with a final extension of 72°C for 7 min. and a quick chill to 4°C. PCR reactions were performed in 15 µl reactions containing 1 µl 50-150 ng DNA, 1xPCR buffer II (50 mM KCl, 10 mM Tris-HCl pH 8.3), 1.5 mM MgCl, 50 pmol each primer and 1U of AmpliTaq DNA Polymerase (Applied Biosystem). The PCR product was amplified using a Mastercycler ep®

gradient S (Eppendorf) thermal cycler. The amplified products were separated in 2% agarose gel. The expected size of the PCR fragment containing a polymorphic deletion within exon 1b was 261 bp.

### Functional analyses of region BRCA1 promoter/5'UTR


**Plasmids.** The 1.5 kb DNA region, encompassing minimal *BRCA1* promoter (promoter α), alternative promoter (β), exons 1a, 1b and intron 1, in wild type and in polymorphic forms, was amplified using the primers 5'→3': TTTTGCTAGCCTTTATGGCAAACCTCAGGTAG and TTTTAAGCTTTCTGTCCAATGAACTTTAAC. The downstream and upstream primers were designed to include *NheI* and *HindIII* sites, respectively (underlined). The amplified products were digested with *NheI* and *HindIII* and ligated into pGL3-Basic reporter vector (Promega) digested with *NheI* and *HindIII*. The pGL3-*BRCA1*-prom plasmids contain the firefly luciferase gene (*luc*) under the transcriptional and translational control of either the wild type or polymorphic *BRCA1* promoter/5'UTR region (Figure 2). The identity of *BRCA1* promoter constructs was confirmed by sequencing. The inserts' nucleotide sequences were compared with the sequence U37574 from GeneBank.



**Fig. 1.** Schematic representation of the 5' region of the *BRCA1* gene and location of sequence alterations found in this gene fragment – 1a and 1b represent two alternative first exons, 2 represents the exon 2 with the translation start site

### Cell culture, transfection and luciferase assay.

Functional analysis of the *BRCA1* promoter/5'UTR region was carried out in human non-small cell lung cancer cell line NCI-H1299 and breast cancer cell line MCF7 (obtained from ATCC). Cells were cultured in DMEM or RPMI-1640 medium (respectively) supplemented with 10% foetal calf serum and kept at 37°C and 5% CO<sub>2</sub>. Cell cultures were plated in 12-well culture dishes at 24 hours prior to transfection. At 40% confluence, lung cancer NCI-H1299 and breast cancer MCF7 cells were transfected with 0.5 µg DNA of wild type or polymorphic reporter vectors using FuGene6 (Roche) transfection reagent according to the manufacturer's instructions. pRL-TK reporter vector coding for *Renilla* luciferase (Promega) was co-transfected with pGL3-*BRCA1*-prom plasmids and served as an internal control. The cells were incubated with FuGene6-DNA for 24 hours. Subsequently the cells were washed in phosphate buffered saline, lysed in 250 µl 1x Passive Lysis Buffer and 20 µl of the cell lysates were assayed using the Dual-Luciferase Reporter Assay System (Promega). Firefly luciferase activity was divided by *Renilla* luciferase activity, which yielded normalized firefly luciferase activity. This normalization helps to minimize the confounding influence of differences in cell number, transfection efficiency, etc. Each pGL3-*BRCA1*-prom plasmid version was



**Fig. 2.** The pGL3 - *BRCA1* – prom plasmid map. The localization of sequence alterations and the recognition sequences of the restriction enzymes used for the cloning are shown. The thick arrow represents the coding region of the firefly luciferase gene (*luc*)

transfected to the three wells of the 12-well plate. The mean and standard deviation from three luciferase measurements were calculated and the statistical significance of the differences were estimated using the *t*-test.

## Results and discussion


One hundred and fifty patients with breast and/or ovarian cancer from Upper Silesia in Poland were screened for sequence alterations in the 5' region of *BRCA1*.

The polymorphic deletion 2223delAAAAA (according to the GeneBank Acc. U37574) within *BRCA1* exon 1b was detected in three families (2%). Two linked nucleotide sequence alterations within the *BRCA1* intron 1 2642A>T, 2743T>C (Acc. U37574) were also detected in 16 patients (18.4%) (Figure 1).

The functional impact of the most frequent sequence variants within the 5' region of *BRCA1* was analysed by the Dual-Luciferase Reporter Assay System (Promega) in the lung cancer cell line (NCI-H1299) and breast cancer cell line (MCF-7). Normalized firefly luciferase activity was significantly lower in the MCF7 cell line compared with the NCI-H1299 cell line (Figure 3).

All tested variants of the *BRCA1* promoter/5' UTR induced expression of the reporter gene at levels very similar to the wild-type sequence in NCI-H1299 cell line ( $2.15 \pm 0.32$  and  $2.02 \pm 0.27$  versus  $1.84 \pm 0.123$ ;  $P=0.19$ , *t*-test; Figure 3). The polymorphic sequences slightly reduced expression of reporter *luc* gene compared with wild-type *BRCA1* promoter/5' UTR in MCF7 cell line ( $0.51 \pm 0.024$  and  $0.55 \pm 0.012$  versus  $0.6 \pm 0.07$ ); however, the differences were not significant ( $P=0.089$ ,  $P=0.263$ , *t*-test, respectively; Figure 3). The evidence from this study suggests that the first polymorphism under investigation could only slightly modulate the levels of expression of the *BRCA1* gene while the second polymorphism (deletion of 5 nucleotides) did not demonstrate any change in functional activity in the experimental system used in this study.

The 5' region of *BRCA1* contains multiple functional domains which may regulate translation, transcription and alternative splicing of *BRCA1* [21, 22]. In this study we analysed the *BRCA1* 5' region and detected several sequence alterations. We cloned the region of interest of the *BRCA1* gene into the reporter plasmid in order to find out if the sequence alterations modulate the expression of the reporter gene. The deletion of five adenines is a major sequence change. It is located in exon 1b, which is an alternative exon present in the mRNA mostly in cancer cells [21, 14]. It may change



NFLA – normalized firefly luciferase activity

SUB – *BRCA1* fragment with two linked nucleotide substitutions: 2642A>T, 2743T>C

DEL – *BRCA1* fragment with deletion: 2223delAAAAA

**Fig. 3.** The normalized activity of the reporter gene (*luc*) under transcriptional and translational control of the wild-type and polymorphic forms *BRCA1* promoter/5'UTR region in NCI-H1299 (grey) and MCF7 (dark grey) cell lines

the secondary structure of the 5'UTR of the alternative mRNA, influencing translation efficiency. However, we did not detect its influence on the reporter gene in either of the two cancer cell lines that we used for the assay. The two linked substitutions are located at the 3' end of intron 1. In principle, they may modulate the efficiency or accuracy of RNA splicing. However, in the case of these linked sequence changes, we observed no influence on reporter gene expression. Therefore, we conclude that the sequence alterations have no major functional impact on *BRCA1* expression. However, we cannot rule out the possibility that they change regulation of *BRCA1* expression in normal cells or when present in their proper chromatin environment.

Interestingly, we noticed that the activity of the reporter gene controlled by *BRCA1* promoter is significantly lower in the MCF7 breast cancer cell line compared with the lung cancer cell line (Fig. 3). Normalized firefly luciferase activity can be regarded as a ratio of experimental promoter activity (*BRCA1* in this case) to the control promoter activity (thymidine kinase gene promoter from herpes simplex virus). This ratio is significantly lower in MCF7 cells. This is consistent with the observation of decreased *BRCA1* protein level in breast cancer cell lines and primary breast carcinomas associated with the increased expression of negative regulators of *BRCA1* promoter [1]. Methylation of the *BRCA1* promoter region also decreases the expression level of the protein [3], but this mechanism is found in a small number of *BRCA1* negative breast cancer specimens [1].

## Acknowledgements

We thank Iwona Matuszczyk for excellent technical assistance.

**Grant sponsor:** State Committee for Scientific Research (KBN, Poland); Grant number 6P05A 14221 (E. Grzybowska)

## References

1. Baldassarre G, Battista S, Belletti B, Thakur S, Pentimalli F, Trapasso F, Fedele M, Pierantoni G, Croce CM and Fusco A. Negative regulation of *BRCA1* gene expression by HMGAI proteins accounts for the reduced *BRCA1* protein levels in sporadic breast carcinoma. *Mol Cell Biol* 2003; 23: 2225-2238.
2. Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S and Karlan BY. *BRCA1* promoter region hypermethylation in ovarian carcinoma: a population-based study. *Cancer Res* 2000; 60: 5329-5333.
3. Bianco T, Chenevix-Trench G, Walsh DC, Cooper JE and Dobrovic A. Tumour-specific distribution of *BRCA1* promoter region methylation supports a pathogenetic role in breast and ovarian cancer. *Carcinogenesis* 2000; 21: 147-151.
4. Brown MA, Xu CF, Nicolai H, Griffiths B, Chambers JA, Black D and Solomon E. The 5' end of the *BRCA1* gene lies within a duplicated region of human chromosome 17q21. *Oncogene* 1996; 12: 2507-2513.
5. Brown MA, Lo LJ, Catteau A, Xu CF, Lindeman GJ, Hodgson S and Solomon E. Germline *BRCA1* promoter deletions in UK and Australian familial breast cancer patients: Identification of a novel deletion consistent with *BRCA1:psiBRCA1* recombination. *Hum Mutat* 2002; 19: 435-442.
6. Dobrovic A and Simpfendorfer D. Methylation of the *BRCA1* gene in sporadic breast cancer. *Cancer Res* 1997; 57: 3347-3350.
7. Grzybowska E, Hemminki K, Szeliga J and Chorazy M. Seasonal variation of aromatic DNA adducts in human lymphocytes and granulocytes. *Carcinogenesis* 1993; 14: 2523-2526.
8. Grzybowska E, Zientek H, Jasinska A, Rusin M, Kozłowski P, Sobczak K, Sikorska A, Kwiatkowska E, Gorniak L, Kalinowska E, Utracka-Hutka B, Wloch J, Chmielik E and Krzyzosiak WJ. High frequency of recurrent mutations in *BRCA1* and *BRCA2* genes in Polish families with breast and ovarian cancer. *Hum Mutat* 2000; 16: 482-490.
9. Grzybowska E, Sieminska M, Zientek H, Kalinowska E, Michalska J, Utracka-Hutka B, Rogozinska-Szczepka J and Kazmierczak-Maciejewska M. Germline mutations in the *BRCA1* gene predisposing to breast and ovarian cancers in Upper Silesia population. *Acta Biochem Pol* 2002; 49: 351-356.
10. Mancini DN, Rodenhiser DI, Ainsworth PJ, O'Malley FP, Singh SM, Xing W and Archer TK. CpG methylation within the 5' regulatory region of the *BRCA1* gene is tumor specific and includes a putative CREB binding site. *Oncogene* 1998; 16: 1161-1169.
11. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene *BRCA1*. *Science* 1994; 266: 66-71.
12. Ozcelik H, To MD, Couture J, Bull SB and Andrulis IL. Preferential allelic expression can lead to reduced expression of *BRCA1* in sporadic breast cancers. *Int J Cancer* 1998; 77: 1-6.
13. Rice JC and Futscher BW. Transcriptional repression of *BRCA1* by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the *BRCA1* promoter. *Nucleic Acids Res* 2000; 28: 3233-3239.
14. Sobczak K and Krzyzosiak WJ. Structural determinants of *BRCA1* translational regulation. *J Biol Chem* 2002; 277: 17349-17358.
15. Signori E, Bagni C, Papa S, Primerano B, Rinaldi M, Amaldi F and Fazio VM. A somatic mutation in the 5'UTR of *BRCA1* gene in sporadic breast cancer causes down-modulation of translation efficiency. *Oncogene* 2001; 20: 4596-4600.
16. Sourvinos G and Spandidos DA. Decreased *BRCA1* expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. *Biochem Biophys Res Commun* 1998; 245: 75-80.
17. Suen TC and Goss PE. Transcription of *BRCA1* is dependent on the formation of a specific protein-DNA complex on the minimal *BRCA1* Bi-directional promoter. *J Biol Chem* 1999; 274: 31297-31304.
18. Thakur S and Croce CM. Positive regulation of the *BRCA1* promoter. *J Biol Chem* 1999; 274: 8837-8843.
19. Thakur S, Nakamura T, Calin G, Russo A, Tamburrino JF, Shimizu M, Baldassarre G, Battista S, Fusco A, Wassell RP, Dubois G, Alder H and Croce CM. Regulation of *BRCA1* transcription by specific single-stranded DNA binding factors. *Mol Cell Biol* 2003; 23: 3774-3787.
20. Thompson ME, Jensen RA, Obermiller PS, Page DL and Holt JT. Decreased expression of *BRCA1* accelerates growth and is often present during sporadic breast cancer progression. *Nat Genet* 1995; 9: 444-450.
21. Xu CF, Brown MA, Chambers JA, Griffiths B, Nicolai H and Solomon E. Distinct transcription start sites generate two forms of *BRCA1* mRNA. *Hum Mol Genet* 1995; 4: 2259-2264.
22. Xu CF, Chambers JA and Solomon E. Complex regulation of the *BRCA1* gene. *J Biol Chem* 1997; 272: 20994-20997.
23. Zheng W, Luo F, Lu JJ, Baltayan A, Press MF, Zhang ZF, Pike MC. Reduction of *BRCA1* expression in sporadic ovarian cancer. *Gynecol Oncol* 2000; 76: 294-300.